Guy-Armel BOUNDA, Hao Zhi Hui, GE Wei Hong, YU Feng
Objective: Assessment of the safety and efficacy of enoxaparin anti-Xa activity in patient with normal renal function, unstable angina and non ST segment elevation myocardial. Methods: At its peak, 4 hours post Enoxaparin administration, blood samples were collected and anti-Xa activity was measured. The German Dade-Behring Corporation SysmexCA-7000 automated coagulation analyzer was used to measure the anti-Xa Enoxaparin activity. The clinical data of patient were evaluated to assess bleeding and thrombotic adverse events after treatment with Enoxaparin.
Results: A total of 70 patients were eligible for our study, with a mean weight of 65.52±9.97kg (BMI: 18.02~29.24kg/m2). While the minimum anti-Xa activity was 0.3IU/ml, the maximum anti-Xa activity was 1.5IU/ml, and the average anti-Xa activity was 0.62±0.24IU/ml. During the study, 5 (7.2%) patients had minor bleeding events with respective dosage of 0.9~1.2IU/ml, which was below urinary occult blood positive rate in healthy adults (Adults 10.68%; Elderly 17.6%). There was no occurrence of thromboembolic event related to Enoxaparin use.
Conclusion: The Enoxaparin anti-Xa activity ≥ 0.3IU/mL can be achieved when anticoagulant activity is effective with careful patient monitoring. During the treatment, there was no clinically significance of bleeding and thromboembolic events. These findings also show that enoxaparin dosing for the treatment of unstable angina and non ST segment elevation myocardial infarction can be safe and effective at an anti-Xa activity of 0.3 to 0.6 IU/mL.
